Form Bio provides a computational platform that utilizes AI models to optimize AAV gene therapy vector design, significantly reducing development time and costs. The platform enhances drug candidate design, test manufacturing, and IND enabling studies by delivering precise assessments of genomic identity, immunogenicity, and manufacturability.
Funding
$64M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JVFounders
Product
Problem
Developing AAV gene therapies is a time-consuming and expensive process. Optimizing vector design, ensuring manufacturability, and conducting necessary IND-enabling studies present significant challenges.
Solution
Form Bio offers a computational platform that leverages AI models to accelerate and optimize AAV gene therapy development. The platform facilitates rational vector design through _in silico_ assessments of genomic identity, immunogenicity, and manufacturability, enabling exploration of multiple vector designs. By providing detailed analysis of drug substance characterization, multi-candidate comparison, and immunotoxicity analysis, Form Bio helps ensure the production of efficacious and safe drugs with high yield. The platform also streamlines IND-enabling studies, providing critical toxicity and safety data necessary for submission.
Target Audience
The primary target audience includes researchers and companies involved in AAV gene therapy development, specifically those focused on drug candidate design, test manufacturing, and IND-enabling studies.
Features
- AI-powered candidate optimization using large language models and deep learning to analyze billions of therapeutic construct versions.
- _In silico_ tools for assessing vector genomic identity, immunogenicity, and manufacturability.
- Drug substance characterization to analyze the manufactured drug product, including the proportion of full AAV viral genomes.
- Multi-candidate comparison to evaluate the safety, yield, and expression of multiple AAV constructs.
- Immunotoxicity analysis to assess potential risks associated with CpG islands and other viral genomic patterns.
- FORMsightAI for elevating construct manufacturability.